Filing Details

Accession Number:
0000899243-18-004480
Form Type:
4
Zero Holdings:
No
Publication Time:
2018-02-20 06:07:30
Reporting Period:
2018-01-02
Accepted Time:
2018-02-20 06:07:30
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1160308 Savara Inc SVRA Pharmaceutical Preparations (2834) 841318182
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1408498 L David Lowrance 900 S. Capital Of Texas Highway,
Suite 150
Austin TX 78746
Chief Financial Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2018-01-02 31,894 $1.51 33,994 No 4 M Direct
Common Stock Disposition 2018-01-02 3,239 $15.06 30,755 No 4 F Direct
Common Stock Disposition 2018-02-15 4,936 $12.70 25,819 No 4 S Direct
Common Stock Disposition 2018-02-15 2,064 $13.30 23,755 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 F Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Employee Stock Option (right to buy) Disposition 2018-01-02 31,894 $0.00 31,894 $1.51
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
95,684 2026-10-25 No 4 M Direct
Footnotes
  1. The sales reported on this Form 4 for February 15, 2018 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 29, 2017.
  2. The price reported is a weighted average sale price. The sale prices ranged from $12.31 to $12.96.
  3. The price reported is a weighted average sale price. The sale prices ranged from $13.00 to $13.71. The reporting person undertakes to provide Savara Inc., any security holder of Savara Inc., or the staff of the Securities and Exchange Commission, upon receipt of a request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
  4. The shares subject to the option vest and become exercisable in sixteen equal quarterly installments beginning on February 1, 2017.